Neuren Pharmaceuticals Company Top Insiders
| NURPF Stock | USD 12.53 0.00 0.00% |
Neuren Pharmaceuticals employs about 15 people. The company is managed by 15 executives with a total tenure of roughly 80 years, averaging almost 5.0 years of service per executive, having 1.0 employees per reported executive. Examination of Neuren Pharmaceuticals' management performance can provide insight into the company performance.
| Larry Glass CEO CEO, Managing Director |
| Richard Treagus Chairman Executive Chairman of the Board |
Neuren |
Neuren Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.172) % which means that it has lost $0.172 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2746) %, meaning that it generated substantial loss on money invested by shareholders. Neuren Pharmaceuticals' management efficiency ratios could be used to measure how well Neuren Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Neuren Pharmaceuticals Workforce Comparison
Neuren Pharmaceuticals Limited is considered to be number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 94.0. Neuren Pharmaceuticals retains roughly 15.0 in number of employees claiming about 16% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (2.15) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.31) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.31. Neuren Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Neuren Pharmaceuticals Price Series Summation is a cross summation of Neuren Pharmaceuticals price series and its benchmark/peer.
Neuren Pharmaceuticals Notable Stakeholders
A Neuren Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Neuren Pharmaceuticals often face trade-offs trying to please all of them. Neuren Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Neuren Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Larry Glass | CEO, Managing Director | Profile | |
| Richard Treagus | Executive Chairman of the Board | Profile | |
| Jon Pilcher | CFO, Company Secretary | Profile | |
| James Shaw | COO | Profile | |
| Bruce Hancox | Independent Non-Executive Director | Profile | |
| Patrick Davies | Non-Executive Independent Director | Profile | |
| Jenny Harry | Non-Executive Independent Director | Profile | |
| Dianne Angus | Non-Executive Independent Director | Profile | |
| Trevor Scott | Independent Non-Executive Director | Profile | |
| Joseph Horrigan | VP of Clinical Devel. and Medical Affairs | Profile | |
| Lauren CA | CFO Sec | Profile | |
| ACA ACA | MD CEO | Profile | |
| Gerry Zhao | VP Devel | Profile | |
| Liza MD | Chief Officer | Profile | |
| Lawrence Glass | Chief Officer | Profile |
About Neuren Pharmaceuticals Management Performance
The success or failure of an entity such as Neuren Pharmaceuticals often depends on how effective the management is. Neuren Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Neuren management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Neuren management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. The company was incorporated in 2001 and is based in Camberwell, Australia. Neuren Pharmaceutica operates under Biotechnology classification in the United States and is traded on OTC Exchange.
The data published in Neuren Pharmaceuticals' official financial statements usually reflect Neuren Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Neuren Pharmaceuticals. For example, before you start analyzing numbers published by Neuren accountants, it's critical to develop an understanding of what Neuren Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Neuren Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neuren Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Neuren Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Neuren Pharmaceuticals Limited. Please utilize our Beneish M Score to check the likelihood of Neuren Pharmaceuticals' management manipulating its earnings.
Neuren Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Neuren Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Neuren Pharmaceuticals within its industry.Neuren Pharmaceuticals Manpower Efficiency
Return on Neuren Pharmaceuticals Manpower
| Revenue Per Employee | 213.1K | |
| Revenue Per Executive | 213.1K | |
| Net Loss Per Employee | 519.6K | |
| Net Loss Per Executive | 519.6K | |
| Working Capital Per Employee | 466.7K | |
| Working Capital Per Executive | 466.7K |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuren Pharmaceuticals Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Neuren Pink Sheet analysis
When running Neuren Pharmaceuticals' price analysis, check to measure Neuren Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuren Pharmaceuticals is operating at the current time. Most of Neuren Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neuren Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuren Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neuren Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |